Efficacy of Orosol® in the Treatment of Chemo- and Radiation-induced Mucositis.

Inclusion Criteria: * Adult patient, male or female, either * treated with chemotherapy for hematological cancer (leukemia, lymphoma) and suffering from grade 2 to 4 mucositis (according to WHO / NCI-CTCAE), or * treated with radiotherapy or radio-chemotherapy (cisplatin or cetuximab) for head and neck cancer and suffering from grade 2 to 4 mucositis (according to WHO / NCI-CTCAE), * Agreeing not to take any treatment for mucositis other than the treatment proposed in this study, apart from the classic symptomatic treatment for mucositis recommended by WHO. * Able to give informed consent to participate in research. * Beneficiary of a Social Security scheme. Exclusion Criteria: * A woman who is pregnant, breastfeeding, or may be. * Major subject under guardianship, curators, deprived of liberty, or under the safeguard of justice. * Medical and / or surgical history deemed by the investigator to be incompatible with the study because it would invalidate any reliable assessment. * General state of health considered pejorative (Karnofsky index \<60). * Type 1 or type 2 diabetic subject (presence of honey in Orosol®). * Subject on an anticoagulant (AVK or AOD) (interaction of the cranberry contained in Orosol® with anticoagulants (in particular warfarin) with instability of the International Normalized Ratio; the AODs can potentially present the same type of interaction). * History of administration of the treatment (or equivalent) in the study. * Anticipated difficulties in reading / understanding the protocol and its questionnaires. * Subjects in the exclusion period from another clinical trial * Refusal of participation.